Latham & Watkins Advises Nevro in Acquisition by Globus Medical

Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, have announced they have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for US$5.85 per share. The transaction represents a total equity value of approximately US$250 million.

Latham & Watkins LLP is representing the Nevro in the transaction with a corporate deal team led by Orange County partners Daniel Rees and Brian Umanoff, with associates Abby Timmons, AJ Hines, Erik Jensen, Danny Del Giorno, Kirstin Chubb, and Chloe Barr. Advice was also provided on FDA regulatory matters by Washington, D.C. counsel Chad Jennings; on healthcare matters by Bay Area partner Betty Pang; on antitrust matters by Washington, D.C. partners Michael Egge and Lindsey Champlin; on benefits and compensation matters by Bay Area partner James Metz, with associate Nimra Syed; on tax matters by Los Angeles partner Eric Cho, with associate Kathryn Harrington; on intellectual property matters by Bay Area counsel Arielle Singh, with associate Fiona Gillan; on data privacy matters by Bay Area partner Heather Deixler; on finance matters by Los Angeles partner Liz Oh and Houston counsel Ben Gelfand, with associate Tyler Davis; on derivatives matters by New York partners Reza Mojtabee-Zamani and Rafal Gawlowski, with associate Jack Neff; and on sanctions controls matters by Washington, D.C. counsel Ruchi Gill, with associate Juan Miramontes.